The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...

T-DXd outperformed physician’s choice of chemotherapy regardless of patients’ disease burden or time to progression on prior therapy.

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...

In the past 5–10 years there has been a growing trend for substituting conventional 5-fluorouracil with the oral prodrug of 5-fluorouracil, capecitabine, in chemotherapy regimens. This regimen ...

On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ ...

Sorafenib, in combination with capecitabine, had a statistically significant improvement in the median progression-free survival and time-to-progression in comparison with capecitabine/placebo for ...

You might have chemotherapy on its own or with radiotherapy. Fluorouracil, capecitabine, oxaliplatin and irinotecan are drugs used for rectal cancer. All treatments must be fully researched before ...

The FDA has approved Datroway® (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic HR-positive, ...